Skip to main content

Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.

Publication ,  Journal Article
Kenchaiah, S; Pocock, SJ; Wang, D; Finn, PV; Zornoff, LAM; Skali, H; Pfeffer, MA; Yusuf, S; Swedberg, K; Michelson, EL; Granger, CB ...
Published in: Circulation
August 7, 2007

BACKGROUND: In individuals without known cardiovascular disease, elevated body mass index (BMI) (weight/height2) is associated with an increased risk of death. However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality. METHODS AND RESULTS: We examined the influence of BMI on prognosis using Cox proportional hazards models in 7599 patients (mean age, 65 years; 35% women) with symptomatic heart failure (New York Heart Association class II to IV) and a broad spectrum of left ventricular ejection fractions (mean, 39%) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. During a median follow-up of 37.7 months, 1831 patients died. After adjustment for potential confounders, compared with patients with BMI between 30 and 34.9, patients in lower BMI categories had a graded increase in the risk of death. The hazard ratios (95% confidence intervals) were 1.22 (1.06 to 1.41), 1.46 (1.24 to 1.71), and 1.69 (1.43 to 2.01) among those with BMI of 25 to 29.9, 22.5 to 24.9, and < 22.5, respectively. The increase in risk of death among patients with BMI > or = 35 was not statistically significant (hazard ratio, 1.17; 95% confidence interval, 0.95 to 1.43). The association between BMI and mortality was not altered by age, smoking status, or left ventricular ejection fraction (P for interaction >0.20). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema (P for interaction <0.0001). Lower BMI was associated with a greater risk of cardiovascular death and noncardiovascular death. Baseline BMI did not influence the risk of hospitalization for worsening heart failure or due to all causes. CONCLUSIONS: In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

August 7, 2007

Volume

116

Issue

6

Start / End Page

627 / 636

Location

United States

Related Subject Headings

  • Tetrazoles
  • Survival Rate
  • Prognosis
  • Morbidity
  • Middle Aged
  • Male
  • Internationality
  • Humans
  • Heart Failure
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kenchaiah, S., Pocock, S. J., Wang, D., Finn, P. V., Zornoff, L. A. M., Skali, H., … CHARM Investigators. (2007). Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation, 116(6), 627–636. https://doi.org/10.1161/CIRCULATIONAHA.106.679779
Kenchaiah, Satish, Stuart J. Pocock, Duolao Wang, Peter V. Finn, Leonardo A. M. Zornoff, Hicham Skali, Marc A. Pfeffer, et al. “Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.Circulation 116, no. 6 (August 7, 2007): 627–36. https://doi.org/10.1161/CIRCULATIONAHA.106.679779.
Kenchaiah, Satish, et al. “Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.Circulation, vol. 116, no. 6, Aug. 2007, pp. 627–36. Pubmed, doi:10.1161/CIRCULATIONAHA.106.679779.
Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LAM, Skali H, Pfeffer MA, Yusuf S, Swedberg K, Michelson EL, Granger CB, McMurray JJV, Solomon SD, CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007 Aug 7;116(6):627–636.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

August 7, 2007

Volume

116

Issue

6

Start / End Page

627 / 636

Location

United States

Related Subject Headings

  • Tetrazoles
  • Survival Rate
  • Prognosis
  • Morbidity
  • Middle Aged
  • Male
  • Internationality
  • Humans
  • Heart Failure
  • Follow-Up Studies